Dupilumab in the treatment of dystrophic epidermolysis bullosa: off‐label use in a pediatric patient

International Journal of DermatologyEarly View Correspondence Dupilumab in the treatment of dystrophic epidermolysis bullosa: off-label use in a pediatric patient Joana Xará MD, Corresponding Author Joana Xará MD [email protected] Dermatology Department, Coimbra University Hospital Center, Coimbra, PortugalSearch for more papers by this authorMaria Relvas MD, Maria Relvas MD Dermatology Department, Coimbra University Hospital Center, Coimbra, PortugalSearch for more papers by this authorCarolina Figueiredo MD, Carolina Figueiredo MD Dermatology Department, Coimbra University Hospital Center, Coimbra, PortugalSearch for more papers by this authorJoana Calvão MD, Joana Calvão MD orcid.org/0000-0002-1161-269X Dermatology Department, Coimbra University Hospital Center, Coimbra, PortugalSearch for more papers by this authorMariana Batista MD, Mariana Batista MD orcid.org/0000-0003-3442-615X Dermatology Department, Coimbra University Hospital Center, Coimbra, PortugalSearch for more papers by this authorLeonor Ramos MD, Leonor Ramos MD Dermatology Department, Coimbra University Hospital Center, Coimbra, PortugalSearch for more papers by this author Joana Xará MD, Corresponding Author Joana Xará MD [email protected] Dermatology Department, Coimbra University Hospital Center, Coimbra, PortugalSearch for more papers by this authorMaria Relvas MD, Maria Relvas MD Dermatology Department, Coimbra University Hospital Center, Coimbra, PortugalSearch for more papers by this authorCarolina Figueiredo MD, Carolina Figueiredo MD Dermatology Department, Coimbra University Hospital Center, Coimbra, PortugalSearch for more papers by this authorJoana Calvão MD, Joana Calvão MD orcid.org/0000-0002-1161-269X Dermatology Department, Coimbra University Hospital Center, Coimbra, PortugalSearch for more papers by this authorMariana Batista MD, Mariana Batista MD orcid.org/0000-0003-3442-615X Dermatology Department, Coimbra University Hospital Center, Coimbra, PortugalSearch for more papers by this authorLeonor Ramos MD, Leonor Ramos MD Dermatology Department, Coimbra University Hospital Center, Coimbra, PortugalSearch for more papers by this author First published: 25 August 2023 https://doi.org/10.1111/ijd.16821 Conflict of interest: None. Funding source: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Clawson RC, Duran SF, Pariser RJ. Epidermolysis bullosa pruriginosa responding to dupilumab. JAAD Case Rep. 2021; 16: 69–71. 2Papanikolaou M, Onoufriadis A, Mellerio JE, Nattkemper LA, Yosipovitch G, Steinhoff M, et al. Prevalence, pathophysiology and management of itch in epidermolysis bullosa. Br J Dermatol. 2021; 184(5): 816–825. 3Beck LA, Deleuran M, Bissonnette R, de Bruin-Weller M, Galus R, Nakahara T, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022; 23(3): 393–408. 4Hendricks AJ, Yosipovitch G, Shi VY. Dupilumab use in dermatologic conditions beyond atopic dermatitis—a systematic review. J Dermatolog Treat. 2021; 32(1): 19–28. 5Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017; 171(1): 217–228.e13. Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation